One can get caught up in whether $0.08 is fair and reasonable or whether the Board and/or management should be penalised rather than rewarded. Mind you controversy around providing Loan Shares and /or Options as long term incentives for directors and management is rather passè. The bigger question is do you want to be caught out on the wrong side of a blackout. With apologies to GoT, Blackout is Coming.
We know the Phase 2 in DMD is an open label and the end is in sight: one patient having completed dosing and the two month monitoring period. The opportunity to report early is an option only requiring meaningful interpretation from a sufficient number of patients to have completed their dosing. Could preliminary assessments have already been made which simply require confirmation through patient 2, 3, 4....... How many is sufficient? One clue is that its less than nine.
Could the $0.08, however, be smoke and mirrors to hoodwink investors or do we take it at face value that its an ESOP to incentivize employees? When the Blackout has descended surely a Trading Halt will follow. Who wants to be on the wrong side of the Wall if the clinical trial reports meaningful clinical data.
ANP Price at posting:
4.6¢ Sentiment: Buy Disclosure: Held
